Accounted for KRW 25.9 billion out of KRW 59.6 billion in total domestic probiotic exports in 2023, securing the top spot
Holds the highest number of Korean probiotic strains listed under the U.S. FDA GRAS, marking its 11th anniversary in Denmark
DUOLAC, South Korea's leading probiotic brand, has once again claimed the top position in exports for the 11th consecutive year, spearheading the global expansion of K-probiotics. Cell Biotech, the pioneering company in the microbiome sector, announced on the 12th that its Korean probiotic brand, DUOLAC, has maintained its No. 1 position in domestic probiotic exports for 11 straight years.
According to the 2023 food production statistics released by the Ministry of Food and Drug Safety on August 1st, the total export value of domestic probiotics reached KRW 59.6 billion, with Cell Biotech achieving KRW 25.9 billion in exports, firmly establishing itself as the leading domestic company in the field. This marks the highest export value for Cell Biotech since tracking began in 2013, further cementing its reputation as the nation's top probiotic company.
Cell Biotech exports Korean probiotics to 55 countries worldwide, showcasing the strength of 'Korean probiotics' in a global market dominated by foreign giants like DuPont Danisco from the U.S. and Chr. Hansen from Denmark.
Notably, DUOLAC has secured a 2nd place market share in Denmark, the home of probiotics. This year marks the 11th anniversary of DUOLAC's launch in Denmark, where Cell Biotech has established a subsidiary, positioning it as a strategic base for expanding exports throughout Europe. Beyond Korea, DUOLAC is proving the power of Korean probiotics on a global scale, solidifying its position as South Korea’s leading probiotic brand, beloved by people worldwide.
In February, the Korean probiotics exported by Cell Biotech gained global attention by achieving the highest number of probiotic strains listed under the U.S. FDA's GRAS (Generally Recognized As Safe) certification. The FDA GRAS is the highest safety recognition by the U.S. Food and Drug Administration, known for its rigorous verification process, making it extremely challenging to achieve. To date, only about 70 probiotic strains have been listed under GRAS, 11 of which are Korean strains from Cell Biotech.
Furthermore, leveraging 29 years of accumulated research expertise, Cell Biotech is developing innovative treatments such as the colorectal cancer drug 'PP-P8' using Korean probiotics, showcasing world-class probiotic development technology and manufacturing know-how. Through the DUOLAC brand, Cell Biotech offers scientifically formulated life-cycle tailored products, addressing the gut microbiome needs of pregnant women, newborns, infants, children, and adults worldwide.
Jung Myung-jun, CEO of Cell Biotech, stated, "As the representative company that first achieved the localization of probiotics in South Korea, a barren land for probiotics, we take great pride in promoting the excellence of Korean probiotics globally. We are deeply grateful for achieving the remarkable milestone of being the world’s No. 1 exporter for 11 consecutive years. Moving forward, we will continue to harness the strength of K-probiotics to secure leadership in the global probiotics market."